Answers are grounded in this paper and cite their sources.
Cardiometabolic multimorbidity (CMM) is closely associated with various metabolic factors, including lipid metabolism disorders, abnormal glucose metabolism, and insulin resistance. With the development of metabolic psychiatry, the relationship between metabolic abnormalities and mental health has attracted increasing attention, highlighting the importance of considering both metabolic factors and psychological burden in the comprehensive assessment of CMM. The cholesterol-high-density lipoprotein-glucose (CHG) index is a novel indicator of metabolic burden derived from total cholesterol, high-density lipoprotein cholesterol, and fasting blood glucose levels. This study aimed to investigate the joint association of the CHG index and depressive symptoms with prevalent CMM. We analyzed data from adults from the 2005–2018 National Health and Nutrition Examination Survey. The CHG index was calculated using total cholesterol, high-density lipoprotein cholesterol, and fasting glucose levels. Psychological burden was assessed using the 9-item Patient Health Questionnaire (PHQ-9), with a score ≥ 10 indicating clinically relevant depressive symptoms. CMM was defined as having at least two cardiometabolic conditions, including diabetes, coronary heart disease, and stroke. Among 12,786 participants (median age, 47 years; 51.03% women), a higher CHG index (adjusted OR = 1.87, 95% CI: 1.47–2.37) and clinically relevant depressive symptoms (adjusted OR = 2.36, 95% CI: 1.74–3.21) were each associated with higher odds of CMM. In the joint analysis, compared with participants with a CHG index < 5.22 and a PHQ-9 score < 10, participants with both a higher CHG index and clinically relevant depressive symptoms had higher odds of CMM (adjusted OR = 4.43, 95% CI: 2.96–6.64). ROC analysis revealed that the combined model had the highest AUC (0.913, 95% CI: 0.901–0.925). Relative to the base model, the combined model yielded a continuous NRI of 0.603 (95% CI: 0.488–0.717) and an IDI of 0.028 (95% CI: 0.012–0.044). These findings suggest modest incremental discrimination of prevalent CMM. Our findings indicate that individuals with both an elevated CHG index and clinically relevant depressive symptoms have higher odds of prevalent CMM. Combined consideration of lipid dysregulation, glycemic abnormalities, and depressive symptom burden may provide complementary information for identifying individuals with prevalent CMM.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: